Neuronascent to Present New Parkinson’s Model Data at AAIC 2023 for the Alzheimer’s Disease
ROCKVILLE, Md., June 28, 2023 (GLOBE NEWSWIRE) — Neuronascent Inc., today announced its abstract titled, Clinical Stage Alzheimer’s therapy, NNI-362 Promotes TH+ Neurons Associated with a Reversal of Motor Deficits in AAV-Alpha Synuclein Model, Leaving Alpha Synuclein Unchanged has been accepted for a poster presentation at the Alzheimer’s Association International Conference (AAIC) to be held…
Neuronascent to Present New Parkinson’s Model Data at AAIC 2023
Neuronascent Inc. is making waves in the field of neurology with its groundbreaking research and cutting-edge therapies. The company’s latest abstract, titled “Clinical Stage Alzheimer’s therapy, NNI-362 Promotes TH+ Neurons Associated with a Reversal of Motor Deficits in AAV-Alpha Synuclein Model, Leaving Alpha Synuclein Unchanged,” has been accepted for presentation at the prestigious Alzheimer’s Association International Conference (AAIC) in 2023.
This abstract highlights Neuronascent’s innovative approach to treating Alzheimer’s disease by targeting TH+ neurons and reversing motor deficits in an AAV-Alpha Synuclein model. The results of this study have the potential to revolutionize the treatment of Alzheimer’s and provide hope for millions of patients and their families.
In addition to their work in Alzheimer’s disease, Neuronascent will also be presenting new data on a Parkinson’s model at AAIC 2023. This further demonstrates the company’s commitment to advancing the field of neurology and developing effective therapies for a range of neurodegenerative disorders.
Effect on Individuals
Individuals affected by Alzheimer’s or Parkinson’s disease may benefit greatly from Neuronascent’s research and therapies. The presentation of new data at AAIC 2023 indicates progress in the development of treatments that could potentially improve symptoms, reverse deficits, and ultimately slow the progression of these debilitating diseases.
Effect on the World
Neuronascent’s research has the potential to have a significant impact on the field of neurology and the treatment of neurodegenerative diseases worldwide. By presenting new data on both Alzheimer’s and Parkinson’s models at AAIC 2023, the company is contributing to the global effort to find effective therapies for these conditions, bringing hope to millions of individuals and their families around the world.
Conclusion
Neuronascent’s upcoming presentation at AAIC 2023 is a testament to the company’s dedication to advancing the field of neurology and developing innovative therapies for Alzheimer’s and Parkinson’s diseases. The research and data being shared have the potential to transform the way these conditions are treated and improve the lives of countless individuals worldwide.
